Study may lead to a novel treatment strategy for inflammatory diseases by manipulating IκBζ function

In the normal small intestine, the levels of SFB and Th17 cells are both maintained constant as they counterbalance each other. Th17 cells release IL-17 to limit unwanted expansion of SFB, whereas decrease in the number of SFB eases the restrictive action of Th17 cells. The research group found that this elaborate control system owes to the presence of healthy IECs. IECs that lack IκBζ gene fail to exert anti-bacterial effects in response to IL-17 even though the cytokine is plentifully produced by increased Th17 cells. They demonstrated that lack of IκBζ in IECs leads to impairment in the two IL-17-mediated defense machineries in the gut: the production of IgA and the maintenance of Paneth cell integrity.

Gut epithelial cells are aligned as a single layer. This thin layer is beneficial for nutrient absorption, but vulnerable to invasion. It requires a strong defense mechanism against invasive pathogens. Besides, these cells have to control the growth of microbes in a flexible manner as needed."

Soh Yamazaki, Ph.D., lead author of the paper, Associate Professor of the Toho University School of Medicine

"We hope that our study will lead to the development of a novel strategy to treat inflammatory diseases by manipulating the function of IκBζ," said the last author Hiroyasu Nakano, M.D., Ph.D. Professor of the Toho University School of Medicine. The finding was published online on August 24, 2022 in the journal Mucosal Immunology.

Journal reference:

Yamazaki, S., et al. (2022) IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies. Mucosal Immunology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Newly identified gene signature helps assess cancer risk and optimize treatment